Main Speakers


Catherine ‘Lynn’ Hedrick, PhD

Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
http://nuclearreceptorresearchnetwork.org/wp-content/uploads/2015/04/Lynn-Hedric-1-160x160.png

Dr. Catherine ‘Lynn’ Hedrick received her B.S. in Biology from Salem College in Winston-Salem, North Carolina in 1984. She received her Ph.D. in Biochemistry from Wake Forest University School of Medicine in 1992, where she performed her graduate research on LDL cholesterol metabolism in the laboratory of Dr. Lawrence Rudel. From 1992 to 1995, she performed her postdoctoral research on HDL metabolism in the laboratory of Dr. Aldons ‘Jake' Lusis at UCLA. From 1995 to 1999, she worked as a junior faculty member in the Division of Cardiology at UCLA, where her research focused on endothelial cell responses to lipoproteins. In 1999, Dr. Hedrick joined the faculty at the University of Virginia in the Departments of Pharmacology, Medicine, and Molecular Physiology and Biological Physics. While at UVA, she rose through the academic ranks to Professor, and in 2009, was awarded the Harrison Chair of Molecular Physiology and Biological Physics at the University of Virginia. As a member of the Robert M. Berne Cardiovascular Center, her research focused on endothelial and monocyte responses to lipoproteins in atherosclerosis. Dr. Hedrick joined the faculty of the La Jolla Institute for Allergy and Immunology (LJI) in La Jolla, CA in the Division of Inflammation Biology in late 2009, as her research began shifting more towards immunology. Dr. Hedrick’s research laboratory at LJI focuses on monocyte and T lymphocyte function in cancer and cardiovascular disease.
Website Hedrick lab


Myles A. Brown

Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
http://nuclearreceptorresearchnetwork.org/wp-content/uploads/2015/04/miles-brown-1-160x160.png

Dr. Myles Brown is Director of the Center for Functional Cancer Epigenetics at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He obtained his BS in Biology from Yale and his MD from Johns Hopkins. Following training in internal medicine at the Brigham and Women’s Hospital, a fellowship in medical oncology at the Dana-Farber and postdoctoral research at MIT, he joined the staff of the Dana-Farber and the faculty of Harvard Medical School. Dr. Brown's research is focused on understanding the factors underlying the hormone dependence of breast and prostate cancers. He is recognized for three seminal discoveries including the role of p160 co-activators in steroid receptor action; the dynamic nature of co-regulator function; and the predominance of steroid receptors as enhancer- rather than promoter-binding factors.
Website Myles Brown lab


Philippa T.K. Saunders

MRC Centre for Inflammation Research, The Queen’s Medical Research Institute, Edinburgh, UK
http://nuclearreceptorresearchnetwork.org/wp-content/uploads/2015/04/spreker-4-1-160x160.png

Philippa Saunders obtained a PhD from the University of Cambridge and then undertook postdoctoral fellowships at the University of Florida and the Institute of Zoology in London. After coming to Edinburgh she established an independent research group within the MRC Human Reproductive Sciences Unit exploring the mechanisms that underlie steroid-dependent impacts on reproductive health in men and women. Philippa Saunders served as Head of the University Centre for Reproductive Biology from 2007-2011 and Inaugural Director of the MRC Centre for Reproductive Health (2011-2012). In 2012 she was appointed as Dean of Postgraduate Research for the College of Medicine and Veterinary Medicine.
Website Saunders lab


Stephan Herzig

IDC Institute for Diabetes and Cancer IDC, Helmholtz Center Munich, Germany
http://nuclearreceptorresearchnetwork.org/wp-content/uploads/2015/04/spreker-3-1-160x160.png

Prof. dr. Stephan Herzig is the director of the new Institute for Diabetes and Cancer at Helmholtz Zentrum München. He assumed this position on January 1, 2015. The new institute will further expand the research topic of diabetes at the Center. Herzig’s objective is to study the complications and comorbidities of this metabolic disease.
Website Herzig lab


Sebastiaan Meijsing

Max Planck Institute for Molecular Genetics, Berlin, Germany
http://nuclearreceptorresearchnetwork.org/wp-content/uploads/2015/04/spreker-2-1-160x160.png

Dr. Sebastiaan Meijsing is group leader at the Max Planck Institute for molecular genetics. He studied in Leiden, the Netherlands, and obtained his PhD from the Humboldt University Berlin for work on transcriptional silencing. Subsequently, he joined the lab of Keith Yamamoto where he studied mechanisms that regulate the dynamic association of the glucocorticoid receptor with DNA and the role of DNA as an allosteric ligand, which modulates the structure and activity of associated proteins. His current work is aimed at understanding how the integration of signals fine-tunes the activity of the glucocorticoid receptor towards individual genes and at linking genomic binding events to the transcriptional regulation of endogenous target genes.
Website Meijsing lab